Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia
In this phase 3, placebo-controlled trial, romiplostim was efficacious in treating CIT. (Funded by Amgen and the Biomedical Advanced Research and Development Authority; RECITE ClinicalTrials.gov number, NCT03362177.).
Authors
- F. Scotté
- Melissa Eisen
- Johnny Francisco Cordeiro Camargo
- Cesar Gregorio Muñoz (ORCID: https://orcid.org/0000-0003-1959-0306)
- I. Korantzis
- Gerald A. Soff (ORCID: https://orcid.org/0000-0002-8781-903X)
- Beatriz González Astorga
- Giuliano Santos Borges
- Hanny Al-Samkari
- Kejia Wang
- David J. Kuter
- Cagatay Arslan
- Çağlayan Geredeli
Institutions
- Amgen (United States) (US)
- Izmir University (TR)
- Institut Gustave Roussy (FR)
- Massachusetts General Hospital (US)
- Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (ES)
- St. Luke's Hospital (GR)
- University of Miami Health System (US)
- Instituto de Investigación Biosanitaria de Granada (ES)
- Istinye University (TR)
- HM Hospitales (ES)
- Camilo José Cela University (ES)
- Hospital Universitario HM Sanchinarro (ES)
- Instituto de Oncologia do Paraná (BR)
- Gaziosmanpaşa Taksim Eğitim ve Araştırma Hastanesi (TR)
- Sylvester Comprehensive Cancer Center (US)
- Centro de Pesquisas Oncológicas (BR)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2026-03-11
- DOI
- https://doi.org/10.1056/nejmoa2511882
- Citations
- 1
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 35.41